Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6645913 | 0.84 | MAPT (0.53) | HCAR3MAPTRAB9AKDM4EADRA2A | |
| SCHEMBL26846315 | 0.84 | PIK3CG (0.50) | HCAR3MAPTRAB9AKDM4EADRA2A | |
| SCHEMBL10293613 | 0.83 | HCAR3 (0.57) | HCAR3MAPTRAB9AKDM4EADRA2A | |
| SCHEMBL23182690 | 0.81 | RAB9A (0.50) | MAPTRAB9AKDM4EADRA2AADRA2B | |
| SCHEMBL20613270 | 0.81 | RAB9A (0.50) | MAPTRAB9AKDM4EADRA2AADRA2B | |
| SCHEMBL14985165 | 0.81 | RAB9A (0.55) | MAPTRAB9AKDM4EADRA2AADRA2B | |
| SCHEMBL10604098 | 0.80 | HCAR3 (0.59) | HCAR3MAPTRAB9AKDM4EADRA2A | |
| Bromide SCHEMBL10609035 | 0.79 | HCAR3 (0.58) | HCAR3MAPTRAB9AKDM4EADRA2A | |
| SCHEMBL22607265 | 0.78 | RAB9A (0.47) | MAPTRAB9AKDM4EADRA2AADRA2B | |
| SCHEMBL12327200 | 0.78 | HCAR3 (0.58) | HCAR3MAPTRAB9AKDM4EADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196975-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023064584-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-3798214-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2021-03-31 | — | — | EP | disclosed |
| WO-2021055749-A1 | THERAPEUTIC CONJUGATES | TOTUS MEDICINES INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| EP-3169687-B1 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | ADVENCHEN PHARMACEUTICALS NANJING LTD (CN) | 2019-01-02 | — | — | EP | disclosed |
| US-9926314-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2018-03-27 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| US-20070197619-A1 | Ion Channel Modulators | WYETH | 2007-08-23 | — | — | US | disclosed |
| US-20070072843-A1 | For treating asthma and improving insulin sensitivity | ADENOSINE THERAPEUTICS, LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070072843-A1 | For treating asthma and improving insulin sensitivity | ADENOSINE THERAPEUTICS, LLC | 2007-03-29 | — | — | US | disclosed |
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADENOSINE THERAPEUTICS, LLC | 2007-03-22 | — | — | US | disclosed |
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADENOSINE THERAPEUTICS, LLC | 2007-03-22 | — | — | US | disclosed |
| US-7186727-B2 | Pyridyl-substituted spiro-hydantoin compounds and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| WO-2005097112-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005087228-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087750-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADORA2B, ADORA2A, ADORA3 | HCAR3 93/4885MAPT 4515/4885RAB9A 2666/4885 |
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | HCAR3 4192/4885MAPT 2665/4885RAB9A 1091/4885 |
| US-20070197619-A1 | Ion Channel Modulators | CACNA1B, CACNA1C, TRPV1 | HCAR3 366/4885MAPT 490/4885RAB9A 1595/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | HCAR3 150/4885MAPT 2827/4885RAB9A 1354/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | HCAR3 3391/4885MAPT 3418/4885RAB9A 701/4885 |
| US-20070072843-A1 | For treating asthma and improving insulin sensitivity | ADORA2B, GPR119, ADORA2A | HCAR3 82/4885MAPT 4850/4885RAB9A 2745/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | HCAR3 870/4885MAPT 4883/4885RAB9A 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.